
GSK Earnings
GSK plc
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of GSK plc(GSK) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of GSK plc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: GBP
Actual
Estimate
Surprise Analysis
FY2025Q1 | 2025-04-30 | Pre-Market | 1.08 | 1.13 | +4.63 | 7.46B | 7.52B | +0.82 | +2.26 | -0.31 |
FY2024Q4 | 2025-02-05 | Pre-Market | 0.53 | 0.59 | +11.32 | 7.75B | 8.12B | +4.73 | +8.21 | +3.53 |
FY2024Q3 | 2024-10-30 | Pre-Market | 1.16 | 1.29 | +11.21 | 8.01B | 8.01B | +0.06 | -3.04 | -3.01 |
FY2024Q2 | 2024-07-31 | - | 1.00 | 1.09 | +9.00 | 7.49B | 7.88B | +5.21 | -2.51 | -2.74 |
FY2024Q1 | 2024-05-01 | - | 0.94 | 1.09 | +15.96 | 7.05B | 7.36B | +4.45 | +2.73 | +6.54 |
FY2023Q4 | 2024-01-31 | - | 0.76 | 0.72 | -5.26 | 7.62B | 8.05B | +5.65 | +0.90 | +6.80 |
FY2023Q3 | 2023-11-01 | - | 1.09 | 1.26 | +15.60 | 7.73B | 8.15B | +5.43 | -3.14 | -2.02 |
FY2023Q2 | 2023-07-26 | - | 0.85 | 0.97 | +14.12 | 6.80B | 7.18B | +5.63 | +0.48 | -2.16 |
- | 2023-04-26 | - | 0.85 | 0.90 | +5.88 | - | - | - | -2.66 | -1.52 |
- | 2023-02-01 | - | 0.59 | 0.64 | +8.47 | - | - | - | +0.65 | +2.58 |
GSK Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, GSK plc reported performance for FY2025Q1, announced on 2025-04-30. The company achieved an EPS of 1.13, compared to analyst estimates of 1.08 by 4.63% . Revenue for the quarter reached 7.52B compared to expectations of 7.46B by 0.82% .
The stock price reacted with a 2.26% one-day change and a -0.31% five-day change following the earnings release. These movements reflect market reaction in GSK plc growth trajectory and strategic initiatives.
GSK Earnings Forecast
Looking ahead, GSK plc(GSK) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q2 project quarter revenue of 7.93B and an EPS of 1.15.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -1.61%, while EPS estimates have been Revise Downward by -1.03%. For the upcoming Q2 2025, revenue estimates have been adjusted Revise Downward by -0.52% . These revisions correlate with a 8.12% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in GSK plc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between GSK's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Downward

-1.61%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-1.03%
In Past 3 Month
Revenue Estimates for Q2 2025
Revise Downward

-0.52%
In Past 3 Month
Stock Price
Go Up

+8.12%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:32.32B
--
EPS Estimate-Annual FY 2025:1.66
—
Stock Price41.03
GSK Revenue and EPS Performance: A Historical Perspective
GSK plc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q1 (2025-04-30,Pre-Market):
EPS: 1.13 (Actual) vs.1.08 (Estimate) (4.63%)
Revenue: 7.52B (Actual) vs. 7.46B (Estimate) (0.82%)
Price Reaction: 2.26%(1-Day), -0.31%(5-Day)
FY2024Q4 (2025-02-05,Pre-Market):
EPS: 0.59 (Actual) vs.0.53 (Estimate) (11.32%)
Revenue: 8.12B (Actual) vs. 7.75B (Estimate) (4.73%)
Price Reaction: 8.21%(1-Day), 3.53%(5-Day)
FY2024Q3 (2024-10-30,Pre-Market):
EPS: 1.29 (Actual) vs.1.16 (Estimate) (11.21%)
Revenue: 8.01B (Actual) vs. 8.01B (Estimate) (0.06%)
Price Reaction: -3.04%(1-Day), -3.01%(5-Day)
Earnings Reaction
The chart below shows how GSK performed 10 days before and after its earnings report, based on data from the past quarters. Typically, GSK sees a -1.40% change in stock price 10 days leading up to the earnings, and a +0.31% change 10 days following the report. On the earnings day itself, the stock moves by +0.39%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2025, the stock changed -2.76% on the day following the earnings release and then changed by -9.11% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
GSK plc (GSK) Q1 2025 Earnings Call Summary
Positive
2025-05-01
GSK's earnings call highlights several positive factors: a dividend increase, a significant share buyback program, and strong specialty medicine sales. Despite some vaccine sales decline, the overall financial performance is solid, with an EPS beat and optimistic guidance. The acquisition of IDRX and a new manufacturing facility further indicate growth potential. While some risks exist, such as regulatory approvals and competitive pressures, the positive sentiment from the Q&A and strategic initiatives suggest a likely stock price increase in the short term.
GSK plc (GSK) Q1 2025 Earnings Call Summary
Neutral
2025-04-30
The earnings call presents a mixed picture. Strong financial performance in specialty medicines and shareholder returns are positives. However, concerns over tariffs, regulatory impacts, and declining vaccine sales balance this out. The Q&A session reveals cautious optimism but lacks specifics on mitigating financial impacts, which may cause investor uncertainty. Overall, the sentiment is neutral, with no strong catalysts for a significant stock price move.
GSK plc (GSK) Q3 2024 Earnings Call Summary
Neutral
2024-10-30
The earnings call reveals mixed financial performance, with growth in Specialty Medicines and HIV sales but a decline in Vaccines. Despite a positive core operating margin and improved cash flow, the significant operating profit drop due to litigation is concerning. The Q&A session indicates management's confidence in long-term growth but lacks clarity on key product timelines and sales expectations. The dividend increase is a positive, but overall, the mixed signals and uncertainties lead to a neutral stock price prediction.
GSK plc (GSK) Q2 2024 Earnings Call Summary
Positive
2024-07-31
The earnings call summary indicates strong financial performance with increased sales, operating profit, and upgraded guidance. Despite short-term issues with Shingrix, management is optimistic about future growth, particularly in China. The Q&A reflects confidence in market leadership and strategic initiatives, though some uncertainty remains. Positive factors like a strong balance sheet, shareholder returns, and improved cash flow outweigh concerns, suggesting a positive stock price movement.
FAQ

What were the key highlights of GSK’s latest earnings report for FY2025Q1?
GSK reported its FY2025Q1 earnings on 2025-04-30, showcasing a revenue of 7.52B against an estimate of 7.46B, resulting in a 0.82% surprise. The EPS was 1.13, surpassing the expected 1.08 by 4.63% . The stock experienced a 2.26% price change on the earnings day and a -0.31% change over the next five days, reflecting market reactions to the results.

How did GSK’s stock price react after the FY2025Q1 earnings release?

What are the revenue and EPS estimates for GSK for 2025/Q2?

How does GSK’s stock price correlate with earnings forecast revisions?

What should investors expect from GSK’s next earnings report?
